Chronic inflammatory bowel disease (IBD) remains one of the most challenging conditions in modern gastroenterology, presenting not only with debilitating symptoms but also with a persistent, long-term risk of severe complications, including the development of bowel cancer. For young adults, the timing of these diseases—typically manifesting between the ages of 15 and 29—is particularly devastating, often striking at a critical juncture for education and early career development. Now, a team of researchers at Charité – Universitätsmedizin Berlin has identified a promising therapeutic target that could prove pivotal in halting these aggressive inflammatory processes. Their findings, which shed new light on the molecular underpinnings of the disease, were recently published in the scientific journal Nature Immunology.
The clinical presentation of the two most common forms of IBD, Crohn’s disease and ulcerative colitis, is often characterized by a cruel unpredictability. Patients frequently endure a cycle of gradual progression interspersed with acute flare-ups, accompanied by severe abdominal cramps, chronic diarrhea, significant weight loss, fatigue, and a profound level of emotional distress. While the conditions share similarities, they differ in their anatomical impact: ulcerative colitis is typically confined to the inner lining of the large intestine, whereas Crohn’s disease can affect the entire thickness of the intestinal wall, often appearing in the small intestine but occasionally extending to the stomach and esophagus. Beyond the immediate physical pain, the chronic, ongoing inflammation causes lasting tissue damage and heightens the risk of oncological complications.
Historically, medical intervention for IBD has relied heavily on broad-spectrum immunosuppression, which aims to dampen the immune system as a whole. While effective for many, this approach carries systemic risks and does not work for every patient. Newer therapeutic strategies have shifted toward precision medicine, seeking to interrupt inflammatory cascades by blocking specific messenger substances—cytokines—that drive the body’s destructive immune response.
Despite decades of research, the exact etiology of these systemic diseases remains elusive. It is widely accepted that IBD arises from a complex interplay between genetic predisposition and environmental triggers. Prof. Ahmed Hegazy, a researcher at Charité’s Department of Gastroenterology, Infectiology and Rheumatology, has dedicated years to unraveling these inflammatory processes. Through his work, he and his team have identified a dangerous synergy between two immune system messenger substances: Interleukin-22, a protein traditionally known for supporting the integrity of the gut lining, and oncostatin M, a signaling molecule heavily involved in tissue repair and cell differentiation.
The Dynamics of an Uncontrolled Chain Reaction
The urgency of this research is driven by the reality of the clinic. "At the clinic, we mainly see young patients who are just beginning their professional lives," says Prof. Hegazy. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
In their investigation, the research team focused on the deleterious effects of oncostatin M. Produced by specific immune cells, this protein acts as a catalyst for other inflammatory factors, effectively setting off a chain reaction that results in an excessive and damaging immune response. One of the most significant observations made by the team was that patients exhibiting high levels of oncostatin M consistently failed to respond to many of the standard therapies currently available. This finding suggests that oncostatin M levels could serve as a valuable biomarker, helping clinicians identify patients with more severe disease phenotypes who are likely to face treatment failure. By focusing on this signaling pathway, the researchers aimed to develop a way to block the protein’s influence.
Over a period of five years, the team meticulously reconstructed how oncostatin M triggers these inflammatory responses. Using a combination of animal models and patient tissue samples, they observed the various stages of chronic intestinal disease. By utilizing state-of-the-art single-cell sequencing, the researchers discovered that the inflamed gut contains a surprisingly large number of cell types equipped with binding sites—or receptors—for oncostatin M, a contrast to what is observed in healthy tissue.
Simultaneously, the team found that additional immune cells begin producing this inflammatory protein, creating a feedback loop. A surprising finding was the role of Interleukin-22. While usually regarded as a protective protein that maintains the gut barrier, the team discovered that in the context of chronic inflammation, Interleukin-22 actually increases the number of receptors for oncostatin M, making the gut lining more sensitive to the damaging signaling molecule. "These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," Prof. Hegazy explains. Through their experimental models, the researchers were able to specifically block the binding sites for oncostatin M, resulting in a clear and measurable reduction in both chronic inflammation and the associated risk of cancer.
Targeted Therapy for High-Risk Patients in Sight
The implications of this study extend to the prevention of colorectal cancer. In analyzing tissue samples from patients who developed cancer as a result of chronic intestinal inflammation, the researchers noted a significantly higher density of oncostatin M receptors around the tumors, compared to the healthy tissue in the surrounding area. This suggests that the signaling pathway fueled by oncostatin M may be a key driver in the transformation of chronic inflammation into malignancy.
However, the researchers remain cautious, noting that IBD is highly heterogeneous. "Chronic inflammatory bowel diseases are highly complex and differ from person to person," says Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology and Rheumatology at Charité. "That’s exactly what makes them so difficult to treat and predict. Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The transition from experimental findings to clinical application is already underway. By identifying the specific mechanisms by which oncostatin M and Interleukin-22 interact, the team has provided a rigorous scientific basis for the development of targeted therapies. The focus is now on disrupting this harmful communication between immune messengers, particularly for those patients suffering from the most severe, treatment-resistant forms of the illness. A clinical trial is currently in progress, investigating an antibody designed to block the receptors for oncostatin M, offering a potential beacon of hope for patients who have exhausted current treatment options. As the medical community continues to refine its understanding of the immune system’s role in IBD, this research marks a significant step toward a future where treatment is not only more effective but also tailored to the specific biological drivers of each individual’s disease.